These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. Bonnekoh B; Schulz M; Franke I; Gollnick H J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303 [TBL] [Abstract][Full Text] [Related]
9. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503 [TBL] [Abstract][Full Text] [Related]
18. [Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group]. Grange F; D'Incan M; Ortonne N; Dalac S; Laroche L; Beylot-Barry M; Delfau-Larue MH; Vergier B; Bagot M; Ann Dermatol Venereol; 2010; 137(8-9):523-31. PubMed ID: 20804896 [TBL] [Abstract][Full Text] [Related]
19. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581 [TBL] [Abstract][Full Text] [Related]
20. Regression of cutaneous intravascular lymphoma with rituximab. Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]